Home Halogens 2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine

2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine

CAS No.:
56741-95-8
Catalog Number:
AG003GGH
Molecular Formula:
C10H8BrN3O
Molecular Weight:
266.0940
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG003GGH
Chemical Name:
2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine
CAS Number:
56741-95-8
Molecular Formula:
C10H8BrN3O
Molecular Weight:
266.0940
MDL Number:
MFCD00813905
IUPAC Name:
2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one
InChI:
InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
InChI Key:
CIUUIPMOFZIWIZ-UHFFFAOYSA-N
SMILES:
O=c1nc(N)[nH]c(c1Br)c1ccccc1
UNII:
J57CTF25XJ
NSC Number:
149027
Properties
Complexity:
343  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
264.985g/mol
Formal Charge:
0
Heavy Atom Count:
15  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
266.098g/mol
Monoisotopic Mass:
264.985g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
67.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.2  
Literature
Title Journal
The expression and functions of toll-like receptors in atherosclerosis. Mediators of inflammation 20100101
Toll-like receptors: role in dermatological disease. Mediators of inflammation 20100101
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World journal of urology 20090601
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Urologic oncology 20050101
Current state of immunotherapy for bladder cancer. Expert review of anticancer therapy 20041201
Current and new strategies in immunotherapy for superficial bladder cancer. Urology 20040901
Superficial bladder cancer therapy. TheScientificWorldJournal 20040101
Characterization of bropirimine O-glucuronidation in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems 20031001
Recognition of pathogen-associated molecular patterns by TLR family. Immunology letters 20030122
In vitro antitumor activity of bropirimine against urinary bladder tumor cells. Anticancer research 20020101
The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. The Journal of urology 20010301
Immunotherapy for bladder cancer. Current urology reports 20010201
Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase. Xenobiotica; the fate of foreign compounds in biological systems 20010101
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral research 19941001
Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. Cancer research 19900215
Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents. Journal of medicinal chemistry 19851201
Antiviral and other bioactivities of pyrimidinones. Pharmacology & therapeutics 19850101
5-substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and interferon-inducing agents. Journal of medicinal chemistry 19800301
Properties